alexa
Reach Us +1-504-608-2390
Photodynamically Inactivated Leishmania As A Potential Novel Carrier For Vaccine Delivery Against Infectious And Non-infectious Diseases | 3452
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Photodynamically inactivated Leishmania as a potential novel carrier for vaccine delivery against infectious and non-infectious diseases

International Conference on Clinical & Cellular Immunology

Kwang Poo Chang

ScientificTracks Abstracts: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.002

Abstract
Leishmania are parasitic protozoa, including those, which cause self-limiting and self-healing simple cutaneous leishmaniasis. These parasites can be photodynamically rendered nonviable, but infection-competent for exploitation as an universal vaccine carrier because they are innately endowed with the following exceptionally favorable attributes: [1] Vaccine adjuvanticity, as indicated by the lasting cell-mediated immunity observed after spontaneous cure in human cutaneous leishmaniasis; [2] Large capacity to express multiple vaccines with post-translational modifications by well-established simple transgenic approaches; [3] Tight protection of the vaccine loads due to their naturally acquired resistance to humoral lytic factors in the mammalian hosts; [4] Homing specificity to the desirable site in the very cells for vaccine processing and presentation, i. e. the phagolysosome of the antigen-presenting cells (macrophages and dendritic cells). This combination of advantages compares Leishmania favorably against viral, bacterial and particulate constructs to serve as a vaccine carrier. Our research objective is to safely harness the above-mentioned attributes of Leishmaina for homing vaccines to antigen-presenting cells, thereby enhancing their immune efficacy. Leishmania are genetically and chemically modified to facilitate their endogenous induction and exogenous loading with photosensitizers, i. e. porphyrins and novel phthalocyanines, thereby rendering them photosensitive to produce ROS for cytolysis to release vaccines in the ROS-resistant phagolysosomes of antigen-presenting cells. Our current efforts are focused on safety/efficacy evaluation of the available constructs and their optimization in vitro and in vivo by using ovalbumin as a surrogate vaccine. We plan to optimize the Leishmania carrier for photodynamic immuno-therapy and -prophylaxis against infectious and non-infectious diseases.
Biography
Kwang Poo Chang has completed his PhD in his twentieth from a Canadian University and postdoctoral studies from the Rockefeller University. He rose to the position of Associate Professor at Rockefeller University and has been a Professor of Microbiology/Immunology, Chicago Medical School since 1983. He has engaged in basic and translational laboratory research of Leishmania and leishmaniasis for >35 years through the support by >20 grant awards from NIH, NSF, WHO, AHA, private Foundations and other sources. He has published >120 papers in reputed journals, served as an editorial board member in 9 different journals and edited/co-edited 4 books/symposium volumes.
Top